Zydelig was approved for several recurrent B-cell cancers, and now new data shows the drug also creates a response in older patients newly diagnosed with CLL or SLL.
Wayne Kuznar
Advertisement
Articles by Wayne Kuznar
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Oncologist Explains What the Rasonque Approval Means for Patients With Metastatic Pancreatic Cancer
2
FDA Approves BESREMi for Essential Thrombocythemia, Expanding Treatment Options
3
FDA Approves Mimrylo for Polycythemia Vera, Offering a New Treatment Approach
4
Weight-Loss Medication Helps Some Breast Cancer Survivors Reach 5% Goal
5